FIGS, Inc. (FIGS), a disruptor in the medical scrubs and apparel sector, has experienced a classic post-pandemic normalization since its high-profile IPO in June 2021. What began as a meteoric rise fueled by heightened healthcare worker demand and remote shopping trends has transitioned into a more mature phase marked by decelerating growth, margin pressures, and a stock price that has shed over 80% from its 2021 peaks. As of the most recent close, the shares trade at levels that reflect investor skepticism about sustained momentum, yet analyst forecasts point to modest revenue recovery amid stabilizing healthcare employment and e-commerce penetration in professional attire. This report dissects the fundamentals, correlating revenue trajectories with profitability erosion, insider behavior, and valuation multiples against a backdrop of broader macroeconomic headwinds like inflation in apparel supply chains and softening U.S. consumer spending.
Revenue Trajectory and Operational Scale
FIGS’ revenue story is inextricably linked to the COVID-19 era. From a modest $110 million in 2019, sales exploded 138% to $263 million in 2020 as healthcare workers sought comfortable, stylish scrubs amid frontline shortages—a direct beneficiary of global pandemic dynamics that boosted healthcare staffing and online apparel sales. This momentum carried into 2021 with 60% growth to $420 million, coinciding with the IPO that valued the company at multibillion-dollar levels on hype around its subscription model and brand loyalty.
However, growth tapered sharply thereafter: 20% to $506 million in 2022, 8% to $546 million in 2023, and a mere 2% to $556 million in 2024. Revenue per employee, a key efficiency metric hovering at $1.5-1.8 million, peaked in 2022 before dipping, underscoring workforce optimization challenges as headcount swelled from 202 in 2020 to 354 in 2023, then contracted 11% to 316 in 2024. This slowdown correlates tightly with post-COVID normalization—U.S. healthcare employment growth slowed from 5% annualized in 2021 to under 2% recently, per Bureau of Labor Statistics data, while competition from legacy players like FIGS’ rivals intensified.
Looking ahead, analysts project a rebound: 7% growth to $595 million in 2025, 5% to $622 million in 2026, and 8% to $669 million in 2027. Revenue per share is expected to climb from $3.28 in 2024 to $4.07 by 2027 (24% cumulative increase), driven by share stability at around 164-169 million outstanding. This anticipates healthcare labor markets stabilizing amid aging demographics and potential policy tailwinds from expanded Medicare under recent U.S. fiscal debates. Yet, the deceleration from triple-digit growth highlights sector maturation, where FIGS must leverage its direct-to-consumer edge to counter macroeconomic pressures like elevated cotton and shipping costs from Red Sea disruptions.
Profitability and Margin Dynamics
Profitability paints a picture of vulnerability beneath revenue steadiness. Gross margins, a critical gauge of pricing power and cost control in commoditized apparel, eroded from 72.3% in 2020 to 67.6% in 2024—a 6% absolute decline—reflecting input inflation and promotional pricing to retain customers. EBT margins followed suit, plummeting from a pandemic-fueled 22.1% to 2.6% in 2024 (88% drop), with net income swinging from $50 million in 2020 to a $9.6 million loss in 2021 (one-off IPO expenses?), then stabilizing at lows like $2.7 million in 2024.
Earnings per share (EPS) mirror this: $0.31 in 2020 to $0.02 in 2024, though projections brighten to $0.18 by 2027 (800%+ from 2024 lows). ROE, measuring equity efficiency, cratered from 73% in 2020 to 0.7% in 2024 but is forecasted at 6.5% by 2026—still modest for a growth stock. These trends correlate with revenue slowdowns; as top-line velocity faded, operating leverage reversed, amplifying fixed costs like marketing. Positively, free cash flow per share remains robust at $0.38 in 2024 (down from $0.50 in 2023 but up from 2022 negatives), supported by operating cash flow of $81 million despite $17 million capex (up 4% YoY, signaling investments in fulfillment).
In a macro context, apparel gross margin compression aligns with global supply chain inflation peaking at 10%+ in 2022-2023, per IMF data, though FIGS’ asset-light model (negative net debt of -$245 million in 2024) provides a buffer uncommon in retail.
Balance Sheet Strength and Cash Generation
FIGS boasts a fortress balance sheet, with shareholders’ equity expanding from $39 million in 2019 to $377 million in 2024 (870% growth) and book value per share rising 780% to $2.23. Net debt remains deeply negative, indicating a cash hoard exceeding borrowings—a rarity that underscores IPO proceeds and cash flow discipline. Working capital ballooned to $293 million in 2024, funding inventory for holiday peaks without leverage (total debt negligible post-2022).
Free cash flow turned positive post-2021 woes ($64 million in 2024), correlating with capex moderation and correlating positively with share price recoveries from 2023 lows around 5. EV/FCF multiples compressed from sky-high 2021 levels to 12.8x in 2024, reflecting maturing cash generation. This liquidity positions FIGS well for buybacks or acquisitions in a fragmented $10 billion U.S. medical apparel market, especially as interest rates ease from Fed pivots.
Valuation Evolution and Stock Performance
Stock price action tells a tale of exuberance to sobriety. From 2021 highs near the mid-40s (amid IPO frenzy) to 2024 lows in the low single digits (down 85%+), shares bottomed amid growth fears before rebounding to current levels—roughly doubling from 2024 troughs but still 75% below IPO. This tracks fundamentals: PS ratios plunged from 14.6x in 2019-2020 to 1.9x in 2024 (87% decline), while PE ballooned to 310x in 2024 on depressed earnings before normalizing to projected 56x by 2027.
EV/Sales at 1.5x currently (projected 2.0x by 2027) suggests undervaluation if growth resumes, but compares unfavorably to peers like Hanesbrands at sub-0.5x amid broader consumer discretionary weakness. The disconnect? Fundamentals lagged hype—revenue per share tripled since 2020, but EPS cratered 94%, dragging multiples.
Insider Activity Signals Caution
Insider transactions reveal zero buys across 2025-2026 periods, with only sells totaling approximately $3.1 million in value. Key executives—Exec Chair (10% owner), CEO (10% owner), and CFO—dominated, offloading 100,000+ shares in clusters (e.g., August 2025: 166,000 shares). These routine 10b5-1 sales coincide with price dips, but the absence of purchases amid a 100%+ rebound from lows raises eyebrows, potentially signaling limited conviction in near-term upside. In a macro lens, executive selling aligns with sector caution as healthcare REITs and staffing firms face reimbursement pressures from U.S. budget talks.
Analyst Outlook and Price Implications
Analysts’ consensus embeds tempered optimism: revenue CAGR of 6% through 2027 with EPS tripling, implying ROA/ROE recovery to 5%/6.5%. Yet price targets cluster conservatively—the mean implies about 12% downside from recent levels, the low 40% downside, and the high 46% upside—reflecting debates on margin repair amid China trade tensions hiking costs.
Strategic Path Forward
FIGS’ path hinges on recapturing 10%+ growth via international expansion (nascent post-IPO) and subscription scaling, buoyed by healthcare’s 4% U.S. GDP share resilience. Risks loom from Amazon encroachment and recessionary spending cuts, but cash flows and low debt enable resilience. At current valuations, the stock offers asymmetric upside if projections hold, though insider sales and margin trends warrant vigilance. Investors should monitor Q1 2026 earnings for capex efficiency and guidance beats, positioning FIGS as a value play in a recovering consumer cycle.
(Word count: 1,128)